Clinical Trials Browser

Terminated × Adenocarcinoma × pembrolizumab × Clear all

Adenocarcinoma, Bronchial Diseases, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms

NCT03997448 2024-02-20

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Phase 2 Terminated

3 enrolled 10 charts

Tumor-Agnostic

Adenocarcinoma

NCT04230954 2022-06-07

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

Phase 2 Terminated

5 enrolled

Gynecologic

Adenocarcinoma, Carcinoma, Squamous Cell, Uterine Cervical Neoplasms, Carcinoma, Adenosquamous

NCT02346955 2020-08-27

MK-6018-001

Phase 1 Terminated

27 enrolled

DermatologicGastrointestinalGenitourinaryGynecologicThoracic

Adenocarcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Melanoma, Neoplasms, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

NCT03407976 2020-07-15

APPEASE

Phase 1 Terminated

5 enrolled

Genitourinary

Adenocarcinoma, Carcinoma, Transitional Cell

Clinical Trials

AcceleRET-Lung

Abemaciclib and Pembrolizumab in Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma: Big Ten Cancer Research Consortium BTCRC-GI18-149

Cabozantinib Plus Pembrolizumab for Recurrent, Persistent and/or Metastatic Cervical Cancer

MK-6018-001

APPEASE